---
title: "Theacrine: Dosing & Vendor Prices — BodyHackGuide"
description: "Theacrine: dosing protocols, mechanism & side effects, 80 PubMed studies. Compare verified vendor prices."
lang: en
json-ld: |
  [
    {
      "@context": "https://schema.org",
      "@type": "BreadcrumbList",
      "itemListElement": [
        {
          "@type": "ListItem",
          "position": 1,
          "name": "Home",
          "item": "https://www.bodyhackguide.co/"
        },
        {
          "@type": "ListItem",
          "position": 2,
          "name": "Compounds",
          "item": "https://www.bodyhackguide.co/compare"
        },
        {
          "@type": "ListItem",
          "position": 3,
          "name": "Theacrine"
        }
      ]
    },
    {
      "@context": "https://schema.org",
      "@type": "MedicalWebPage",
      "name": "Theacrine",
      "description": "Theacrine (1,3,7,9-tetramethyluric acid) is a purine alkaloid structurally related to caffeine, found naturally in Camellia assamica var. kucha — a tea cultivar grown in southern China and northern Vietnam — and in smaller amounts in Cupuaçu (Theobroma grandiflorum) seeds. It shares caffeine's xanthine backbone but carries an extra methyl group at the 9-position and a 2,6,8-trione oxidation pattern, giving it pharmacology that overlaps caffeine's adenosine-receptor antagonism while diverging in dopaminergic tone and tolerance development. The most widely studied form in human trials is the patented ingredient TeaCrine, a ≥98% pure synthetic equivalent used in most commercial nootropic and pre-workout formulas. The practical appeal of theacrine in community use rests on three observations: first, healthy adults taking 200-300 mg daily report stimulation subjectively comparable to 150-200 mg caffeine — but with less jitter, less heart-rate elevation, and a slower onset (~60-90 minutes) that many users describe as \"smoother\" than caffeine's 20-40 minute peak. Second, an 8-week daily-dosing study (Taylor 2016) found no meaningful development of tolerance at 200-300 mg/day, no withdrawal signs on cessation, and no shifts in resting heart rate, blood pressure, liver enzymes, or complete blood count — a tolerance profile that genuinely differs from caffeine, where habitual use produces documented receptor upregulation and dependence within 1-2 weeks. Third, co-administration with caffeine produces synergy: pharmacokinetic data (He 2017) show caffeine roughly doubles theacrine plasma exposure (AUC), likely by slowing hepatic clearance, so 125 mg theacrine + 150 mg caffeine often outperforms either compound alone for perceived focus and endurance. Mechanism is not identical to caffeine. Like caffeine, theacrine antagonizes adenosine A1 and A2A receptors (the primary driver of wakefulness and reduced perception of effort), but rodent models (Feduccia 2012) additionally show dose-dependent increases in nucleus accumbens dopamine and locomotor activation that are blocked by both adenosine and dopamine-D1 antagonists — suggesting a dual adenosinergic-dopaminergic mechanism that caffeine does not fully replicate. This may explain the \"motivation\" quality users report and the absence of downregulation: chronic adenosine blockade alone should produce tolerance, but the concurrent dopaminergic signal appears to counterbalance receptor adaptation over an 8-week horizon. Human clinical data are limited but consistent. A double-blind crossover in habitual caffeine users (Ziegenfuss 2017) showed 300 mg theacrine improved reaction-time Bond-Lader alertness scores without the jitter-axis elevation that 150 mg caffeine produced in the same subjects. A separate 8-week safety and efficacy trial in 60 adults (Kuhman 2015) reported significant improvements in self-rated energy, focus, and concentration versus placebo at 200 and 300 mg/day with no adverse clinical findings. Community-tier evidence (r/Nootropics, forum writeups spanning 2015-2024) tends to converge on 100-200 mg as a mild-stim daily baseline, 250-300 mg for pre-workout or high-focus sessions, and 150 mg + 100 mg caffeine as a common synergy stack. Most users who transition from pure caffeine report similar energy with substantially less afternoon \"crash\" and easier sleep onset if taken before 2 PM. Practical considerations: theacrine is sold as a food-supplement ingredient in the US, EU, Australia, and most of Asia. It is NOT a controlled substance, not a prescription drug, and has no abuse liability signal in animal models. Quality matters — the vast majority of peer-reviewed human data used TeaCrine, a standardized ≥98% pure ingredient; some generic \"theacrine\" bulk powder has been found to be underdosed or contaminated with caffeine (independent COA testing, 2019-2021). Look for products that explicitly cite the TeaCrine trademark and provide a certificate of analysis. Theacrine is often stacked with L-theanine (100-200 mg) for an anxiolytic counterweight, with alpha-GPC (300 mg) for cholinergic contrast, and with dynamine (methylliberine, a faster-acting but shorter-duration analog) for a biphasic energy curve. It is not recommended for pregnancy, breastfeeding, uncontrolled hypertension, or anyone on MAOIs. The safety window at studied doses is wide, but the long-term profile beyond 8 weeks remains formally uncharacterized — community experience over 2-3 years of daily use suggests it holds up, but this is self-report data.",
      "lastReviewed": "2026-05-04T11:34:02.036+00:00",
      "url": "https://www.bodyhackguide.co/compound/theacrine",
      "author": {
        "@type": "Person",
        "name": "BioChonch",
        "url": "https://www.bodyhackguide.co/about",
        "jobTitle": "Founder & Lead Researcher",
        "sameAs": [
          "https://x.com/bodyhackguide",
          "https://reddit.com/r/BodyHackGuide",
          "https://reddit.com/r/BrainHackGuide",
          "https://reddit.com/r/Biohackingher"
        ],
        "worksFor": {
          "@type": "Organization",
          "name": "BodyHackGuide",
          "url": "https://www.bodyhackguide.co"
        }
      },
      "reviewedBy": {
        "@type": "Person",
        "name": "BioChonch",
        "url": "https://www.bodyhackguide.co/about",
        "jobTitle": "Founder & Lead Researcher",
        "sameAs": [
          "https://x.com/bodyhackguide",
          "https://reddit.com/r/BodyHackGuide",
          "https://reddit.com/r/BrainHackGuide",
          "https://reddit.com/r/Biohackingher"
        ],
        "worksFor": {
          "@type": "Organization",
          "name": "BodyHackGuide",
          "url": "https://www.bodyhackguide.co"
        }
      },
      "publisher": {
        "@type": "Organization",
        "name": "BodyHackGuide",
        "url": "https://www.bodyhackguide.co"
      },
      "mainContentOfPage": {
        "@type": "WebPageElement",
        "cssSelector": "main"
      },
      "about": {
        "@type": "Drug",
        "name": "Theacrine",
        "alternateName": [
          "1,3,7,9-tetramethyluric acid",
          "TeaCrine",
          "1,3,7,9-tetramethyl-purine-2,6,8-trione"
        ],
        "description": "Theacrine (1,3,7,9-tetramethyluric acid) is a purine alkaloid structurally related to caffeine, found naturally in Camellia assamica var. kucha — a tea cultivar grown in southern China and northern Vietnam — and in smaller amounts in Cupuaçu (Theobroma grandiflorum) seeds. It shares caffeine's xanthine backbone but carries an extra methyl group at the 9-position and a 2,6,8-trione oxidation pattern, giving it pharmacology that overlaps caffeine's adenosine-receptor antagonism while diverging in dopaminergic tone and tolerance development. The most widely studied form in human trials is the patented ingredient TeaCrine, a ≥98% pure synthetic equivalent used in most commercial nootropic and pre-workout formulas. The practical appeal of theacrine in community use rests on three observations: first, healthy adults taking 200-300 mg daily report stimulation subjectively comparable to 150-200 mg caffeine — but with less jitter, less heart-rate elevation, and a slower onset (~60-90 minutes) that many users describe as \"smoother\" than caffeine's 20-40 minute peak. Second, an 8-week daily-dosing study (Taylor 2016) found no meaningful development of tolerance at 200-300 mg/day, no withdrawal signs on cessation, and no shifts in resting heart rate, blood pressure, liver enzymes, or complete blood count — a tolerance profile that genuinely differs from caffeine, where habitual use produces documented receptor upregulation and dependence within 1-2 weeks. Third, co-administration with caffeine produces synergy: pharmacokinetic data (He 2017) show caffeine roughly doubles theacrine plasma exposure (AUC), likely by slowing hepatic clearance, so 125 mg theacrine + 150 mg caffeine often outperforms either compound alone for perceived focus and endurance. Mechanism is not identical to caffeine. Like caffeine, theacrine antagonizes adenosine A1 and A2A receptors (the primary driver of wakefulness and reduced perception of effort), but rodent models (Feduccia 2012) additionally show dose-dependent increases in nucleus accumbens dopamine and locomotor activation that are blocked by both adenosine and dopamine-D1 antagonists — suggesting a dual adenosinergic-dopaminergic mechanism that caffeine does not fully replicate. This may explain the \"motivation\" quality users report and the absence of downregulation: chronic adenosine blockade alone should produce tolerance, but the concurrent dopaminergic signal appears to counterbalance receptor adaptation over an 8-week horizon. Human clinical data are limited but consistent. A double-blind crossover in habitual caffeine users (Ziegenfuss 2017) showed 300 mg theacrine improved reaction-time Bond-Lader alertness scores without the jitter-axis elevation that 150 mg caffeine produced in the same subjects. A separate 8-week safety and efficacy trial in 60 adults (Kuhman 2015) reported significant improvements in self-rated energy, focus, and concentration versus placebo at 200 and 300 mg/day with no adverse clinical findings. Community-tier evidence (r/Nootropics, forum writeups spanning 2015-2024) tends to converge on 100-200 mg as a mild-stim daily baseline, 250-300 mg for pre-workout or high-focus sessions, and 150 mg + 100 mg caffeine as a common synergy stack. Most users who transition from pure caffeine report similar energy with substantially less afternoon \"crash\" and easier sleep onset if taken before 2 PM. Practical considerations: theacrine is sold as a food-supplement ingredient in the US, EU, Australia, and most of Asia. It is NOT a controlled substance, not a prescription drug, and has no abuse liability signal in animal models. Quality matters — the vast majority of peer-reviewed human data used TeaCrine, a standardized ≥98% pure ingredient; some generic \"theacrine\" bulk powder has been found to be underdosed or contaminated with caffeine (independent COA testing, 2019-2021). Look for products that explicitly cite the TeaCrine trademark and provide a certificate of analysis. Theacrine is often stacked with L-theanine (100-200 mg) for an anxiolytic counterweight, with alpha-GPC (300 mg) for cholinergic contrast, and with dynamine (methylliberine, a faster-acting but shorter-duration analog) for a biphasic energy curve. It is not recommended for pregnancy, breastfeeding, uncontrolled hypertension, or anyone on MAOIs. The safety window at studied doses is wide, but the long-term profile beyond 8 weeks remains formally uncharacterized — community experience over 2-3 years of daily use suggests it holds up, but this is self-report data.",
        "activeIngredient": "Theacrine",
        "administrationRoute": "Oral",
        "mechanismOfAction": "Theacrine's primary pharmacodynamic signature is dual adenosine A1/A2A receptor antagonism, the same mechanism caffeine exploits to reduce perceived fatigue and suppress sleep drive. The 9-methyl and 2,6,8-trione modifications to the xanthine core shift its receptor affinity profile: rodent binding studies (Feduccia 2012) show theacrine binds A1 and A2A with lower affinity than caffeine on a per-molecule basis but produces comparable behavioral activation, suggesting differences in receptor kinetics or downstream coupling. The second mechanism — and the one that most clearly distinguishes theacrine from caffeine — is dopaminergic. In rodent microdialysis experiments, acute theacrine (24-48 mg/kg) increased nucleus accumbens dopamine and locomotor activity. This locomotor response was blocked by the dopamine-D1 antagonist SCH 23390 AND by the adenosine-receptor antagonist DPCPX, indicating the behavioral output requires BOTH adenosine blockade and D1 activation. Caffeine's locomotor effect is blocked only by adenosine antagonism. This divergence plausibly underlies theacrine's subjective \"motivation\" quality and may contribute to the absence of tolerance — because the dopaminergic signal maintains net stimulation even if adenosine-receptor sensitivity adapts. A third, lower-confidence mechanism involves mild adenosine triphosphate (ATP) conservation via inhibition of hepatic and adipose tissue breakdown pathways — the evidence for this is cell-culture tier and has not been verified in human tissue. Theacrine does NOT appreciably inhibit phosphodiesterase at physiological doses (unlike caffeine at high doses), does NOT block the GABA-A receptor, and does NOT significantly modulate serotonin or noradrenaline in available models. Pharmacokinetically, theacrine is orally bioavailable, peaks in plasma at ~60-90 minutes, and has a half-life of 16-20 hours in humans (He 2017) — substantially longer than caffeine's 5-hour half-life. Co-ingestion with caffeine increases theacrine AUC by roughly 100% (likely via shared CYP1A2 metabolism, with caffeine acting as a competitive substrate), while caffeine's own pharmacokinetics remain largely unchanged. This explains the widely-reported synergy of low-dose caffeine + theacrine stacks: caffeine sharpens the onset and extends theacrine's effective exposure without substantially increasing caffeine-specific side effects. Theacrine is metabolized primarily through hepatic demethylation, eventually converging on uric-acid-like terminal products. CYP1A2 is implicated but not exclusive; slow CYP1A2 metabolizers may experience extended duration and should adjust dosing accordingly.",
        "legalStatus": "Not approved for human use — research chemical",
        "warning": "For research purposes only. Not for human consumption."
      }
    },
    {
      "@context": "https://schema.org",
      "@type": "FAQPage",
      "mainEntity": [
        {
          "@type": "Question",
          "name": "How is theacrine different from caffeine?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Theacrine shares caffeine's adenosine A1/A2A antagonism but adds dopaminergic activation (Feduccia 2012, PMID 22771692) and has a 16-20 hour half-life versus caffeine's 5 hours. The practical differences: slower onset (60-90 minutes vs 20-40), less jitter and peripheral stimulation, no measurable tolerance at 8 weeks of daily use (Taylor 2016, PMID 27335344), and no withdrawal on cessation. Many users describe the subjective quality as 'motivation' or 'smooth energy' rather than caffeine's 'alertness.'"
          }
        },
        {
          "@type": "Question",
          "name": "Does theacrine really not build tolerance?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "The 8-week clinical data (Taylor 2016) show no measurable tolerance at 200-300 mg/day — no waning subjective effect, no cardiovascular adaptation, no need for dose escalation. Rodent locomotor data (Feduccia 2012) show the same pattern over 7 days where caffeine produces clear tolerance. The mechanism probably involves the dopaminergic signal counterbalancing adenosine-receptor desensitization. Long-term (>8 week) data are limited, so 'no tolerance ever' overstates the evidence — but across the best-characterized window, the tolerance resistance is real."
          }
        },
        {
          "@type": "Question",
          "name": "What's the optimal dose?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "100-200 mg in the morning is the community-tier sweet spot for most users. The clinical trials used 200-300 mg. Above 300 mg, effects tend to flatten or invert for many users, suggesting dopaminergic receptor saturation. Start at 100 mg for 1-2 weeks, then titrate up only if needed. When stacking with caffeine, reduce the theacrine dose by ~25% because caffeine doubles theacrine AUC (He 2017, PMID 28356193)."
          }
        },
        {
          "@type": "Question",
          "name": "Can I take theacrine every day?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Yes, the 8-week daily dosing trial (Taylor 2016, PMID 27335344) found no tolerance, no adverse clinical findings, and no withdrawal. Most users take it daily without cycling. Some prefer 5 days on / 2 days off for subjective freshness or to preserve sleep on off-days, but there's no pharmacological reason the cycle is necessary."
          }
        },
        {
          "@type": "Question",
          "name": "Will it mess up my sleep?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Almost certainly, if you take it after ~2 PM. The 16-20 hour half-life means a 200 mg morning dose still has ~40% of peak plasma at 10 PM. Take theacrine before noon only, and skip on days when uncompromised sleep is critical. No post-dose sleep aid effectively offsets it — the pharmacokinetics simply don't allow a same-day rescue."
          }
        },
        {
          "@type": "Question",
          "name": "Does it work better with caffeine?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Often yes. Caffeine doubles theacrine plasma AUC (He 2017, PMID 28356193), adds fast-onset alertness, and the combination tested in Ziegenfuss 2017 (PMID 28280478) outperformed either monotherapy for composite attention. A common starter combination is 125 mg theacrine + 100 mg caffeine morning. Reduce your usual caffeine ~30% the first time you add theacrine to avoid cardiovascular overshoot."
          }
        },
        {
          "@type": "Question",
          "name": "Is TeaCrine different from generic theacrine?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "TeaCrine is a ≥98% pure branded ingredient (Compound Solutions) used in most published clinical trials. Generic bulk theacrine has shown variable purity in independent testing — some underdosed, some adulterated with caffeine. If the supplement bottle doesn't cite the TeaCrine trademark and provide a COA, quality is unreliable. The clinical efficacy data technically only cover TeaCrine, not generic material."
          }
        },
        {
          "@type": "Question",
          "name": "Is theacrine legal and safe?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Theacrine is legal as a dietary-supplement ingredient in the US, EU, Canada, Australia, and most of Asia. It's not a controlled substance, not a prescription drug, and has no abuse liability signal in rodent or human studies. Safety at 100-300 mg/day is supported by 8 weeks of clinical exposure with no adverse findings. It is not on the 2024 WADA prohibited list, though competitive athletes should verify with their specific governing body."
          }
        },
        {
          "@type": "Question",
          "name": "Who should avoid it?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Anyone pregnant or breastfeeding, under 18, with uncontrolled hypertension, arrhythmia, or on MAOIs. Relative cautions include treated hypertension, anxiety disorders (dopaminergic activation can be anxiogenic), bipolar disorder, active gout, and concurrent use of strong CYP1A2 inhibitors like fluvoxamine or ciprofloxacin. If you're on any daily medication, check with your prescriber before starting."
          }
        },
        {
          "@type": "Question",
          "name": "What does theacrine stack well with?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "The most evidence-backed pairing is caffeine (see above). L-theanine (100-200 mg) is the most common anxiolytic counterweight. Alpha-GPC (300 mg) adds cholinergic depth for cognitive sessions. Dynamine (100 mg, methylliberine) creates a biphasic energy curve. Rhodiola rosea layers an adaptogen on top. Avoid stacking with other stimulants (DMHA, DMAA, yohimbine) — the sympathomimetic load compounds without additive benefit."
          }
        }
      ]
    },
    {
      "@context": "https://schema.org",
      "@type": "Organization",
      "@id": "https://www.bodyhackguide.co#organization",
      "name": "BodyHackGuide",
      "alternateName": "BHG",
      "url": "https://www.bodyhackguide.co",
      "logo": {
        "@type": "ImageObject",
        "url": "https://www.bodyhackguide.co/logo.png",
        "width": 512,
        "height": 512
      },
      "description": "Evidence-based research reference for peptides and nootropics. 124+ compound profiles, interactive dosing calculators, real-time vendor pricing, and trust-scored vendor reviews scored on a public, reproducible methodology applied to every vendor. BodyHackGuide and BHG Labs share common ownership, and we earn a commission on purchases through our links.",
      "foundingDate": "2024",
      "founder": {
        "@id": "https://www.bodyhackguide.co/about#person"
      },
      "sameAs": [
        "https://x.com/bodyhackguide",
        "https://reddit.com/r/BodyHackGuide",
        "https://reddit.com/r/BrainHackGuide",
        "https://reddit.com/r/Biohackingher",
        "https://discord.gg/Mhq5UdRYBA"
      ],
      "knowsAbout": [
        "Peptide research",
        "Nootropic research",
        "Biohacking",
        "Compound dosing",
        "Vendor transparency"
      ],
      "publishingPrinciples": "https://www.bodyhackguide.co/editorial-standards",
      "ethicsPolicy": "https://www.bodyhackguide.co/editorial-standards",
      "diversityPolicy": "https://www.bodyhackguide.co/editorial-standards"
    },
    {
      "@context": "https://schema.org",
      "@type": "MedicalWebPage",
      "name": "Theacrine",
      "description": "Theacrine (1,3,7,9-tetramethyluric acid) is a purine alkaloid structurally related to caffeine, found naturally in Camellia assamica var. kucha — a tea cultivar grown in southern China and northern Vietnam — and in smaller amounts in Cupuaçu (Theobroma grandiflorum) seeds. It shares caffeine's xanthine backbone but carries an extra methyl group at the 9-position and a 2,6,8-trione oxidation pattern, giving it pharmacology that overlaps caffeine's adenosine-receptor antagonism while diverging in dopaminergic tone and tolerance development. The most widely studied form in human trials is the patented ingredient TeaCrine, a ≥98% pure synthetic equivalent used in most commercial nootropic and pre-workout formulas. The practical appeal of theacrine in community use rests on three observations: first, healthy adults taking 200-300 mg daily report stimulation subjectively comparable to 150-200 mg caffeine — but with less jitter, less heart-rate elevation, and a slower onset (~60-90 minutes) that many users describe as \"smoother\" than caffeine's 20-40 minute peak. Second, an 8-week daily-dosing study (Taylor 2016) found no meaningful development of tolerance at 200-300 mg/day, no withdrawal signs on cessation, and no shifts in resting heart rate, blood pressure, liver enzymes, or complete blood count — a tolerance profile that genuinely differs from caffeine, where habitual use produces documented receptor upregulation and dependence within 1-2 weeks. Third, co-administration with caffeine produces synergy: pharmacokinetic data (He 2017) show caffeine roughly doubles theacrine plasma exposure (AUC), likely by slowing hepatic clearance, so 125 mg theacrine + 150 mg caffeine often outperforms either compound alone for perceived focus and endurance. Mechanism is not identical to caffeine. Like caffeine, theacrine antagonizes adenosine A1 and A2A receptors (the primary driver of wakefulness and reduced perception of effort), but rodent models (Feduccia 2012) additionally show dose-dependent increases in nucleus accumbens dopamine and locomotor activation that are blocked by both adenosine and dopamine-D1 antagonists — suggesting a dual adenosinergic-dopaminergic mechanism that caffeine does not fully replicate. This may explain the \"motivation\" quality users report and the absence of downregulation: chronic adenosine blockade alone should produce tolerance, but the concurrent dopaminergic signal appears to counterbalance receptor adaptation over an 8-week horizon. Human clinical data are limited but consistent. A double-blind crossover in habitual caffeine users (Ziegenfuss 2017) showed 300 mg theacrine improved reaction-time Bond-Lader alertness scores without the jitter-axis elevation that 150 mg caffeine produced in the same subjects. A separate 8-week safety and efficacy trial in 60 adults (Kuhman 2015) reported significant improvements in self-rated energy, focus, and concentration versus placebo at 200 and 300 mg/day with no adverse clinical findings. Community-tier evidence (r/Nootropics, forum writeups spanning 2015-2024) tends to converge on 100-200 mg as a mild-stim daily baseline, 250-300 mg for pre-workout or high-focus sessions, and 150 mg + 100 mg caffeine as a common synergy stack. Most users who transition from pure caffeine report similar energy with substantially less afternoon \"crash\" and easier sleep onset if taken before 2 PM. Practical considerations: theacrine is sold as a food-supplement ingredient in the US, EU, Australia, and most of Asia. It is NOT a controlled substance, not a prescription drug, and has no abuse liability signal in animal models. Quality matters — the vast majority of peer-reviewed human data used TeaCrine, a standardized ≥98% pure ingredient; some generic \"theacrine\" bulk powder has been found to be underdosed or contaminated with caffeine (independent COA testing, 2019-2021). Look for products that explicitly cite the TeaCrine trademark and provide a certificate of analysis. Theacrine is often stacked with L-theanine (100-200 mg) for an anxiolytic counterweight, with alpha-GPC (300 mg) for cholinergic contrast, and with dynamine (methylliberine, a faster-acting but shorter-duration analog) for a biphasic energy curve. It is not recommended for pregnancy, breastfeeding, uncontrolled hypertension, or anyone on MAOIs. The safety window at studied doses is wide, but the long-term profile beyond 8 weeks remains formally uncharacterized — community experience over 2-3 years of daily use suggests it holds up, but this is self-report data.",
      "lastReviewed": "2026-05-04T11:34:02.036+00:00",
      "url": "https://www.bodyhackguide.co/compound/theacrine",
      "author": {
        "@type": "Person",
        "name": "BioChonch",
        "url": "https://www.bodyhackguide.co/about",
        "jobTitle": "Founder & Lead Researcher",
        "sameAs": [
          "https://x.com/bodyhackguide",
          "https://reddit.com/r/BodyHackGuide",
          "https://reddit.com/r/BrainHackGuide",
          "https://reddit.com/r/Biohackingher"
        ],
        "worksFor": {
          "@type": "Organization",
          "name": "BodyHackGuide",
          "url": "https://www.bodyhackguide.co"
        }
      },
      "reviewedBy": {
        "@type": "Person",
        "name": "BioChonch",
        "url": "https://www.bodyhackguide.co/about",
        "jobTitle": "Founder & Lead Researcher",
        "sameAs": [
          "https://x.com/bodyhackguide",
          "https://reddit.com/r/BodyHackGuide",
          "https://reddit.com/r/BrainHackGuide",
          "https://reddit.com/r/Biohackingher"
        ],
        "worksFor": {
          "@type": "Organization",
          "name": "BodyHackGuide",
          "url": "https://www.bodyhackguide.co"
        }
      },
      "publisher": {
        "@type": "Organization",
        "name": "BodyHackGuide",
        "url": "https://www.bodyhackguide.co"
      },
      "mainContentOfPage": {
        "@type": "WebPageElement",
        "cssSelector": "main"
      },
      "about": {
        "@type": "Drug",
        "name": "Theacrine",
        "alternateName": [
          "1,3,7,9-tetramethyluric acid",
          "TeaCrine",
          "1,3,7,9-tetramethyl-purine-2,6,8-trione"
        ],
        "description": "Theacrine (1,3,7,9-tetramethyluric acid) is a purine alkaloid structurally related to caffeine, found naturally in Camellia assamica var. kucha — a tea cultivar grown in southern China and northern Vietnam — and in smaller amounts in Cupuaçu (Theobroma grandiflorum) seeds. It shares caffeine's xanthine backbone but carries an extra methyl group at the 9-position and a 2,6,8-trione oxidation pattern, giving it pharmacology that overlaps caffeine's adenosine-receptor antagonism while diverging in dopaminergic tone and tolerance development. The most widely studied form in human trials is the patented ingredient TeaCrine, a ≥98% pure synthetic equivalent used in most commercial nootropic and pre-workout formulas. The practical appeal of theacrine in community use rests on three observations: first, healthy adults taking 200-300 mg daily report stimulation subjectively comparable to 150-200 mg caffeine — but with less jitter, less heart-rate elevation, and a slower onset (~60-90 minutes) that many users describe as \"smoother\" than caffeine's 20-40 minute peak. Second, an 8-week daily-dosing study (Taylor 2016) found no meaningful development of tolerance at 200-300 mg/day, no withdrawal signs on cessation, and no shifts in resting heart rate, blood pressure, liver enzymes, or complete blood count — a tolerance profile that genuinely differs from caffeine, where habitual use produces documented receptor upregulation and dependence within 1-2 weeks. Third, co-administration with caffeine produces synergy: pharmacokinetic data (He 2017) show caffeine roughly doubles theacrine plasma exposure (AUC), likely by slowing hepatic clearance, so 125 mg theacrine + 150 mg caffeine often outperforms either compound alone for perceived focus and endurance. Mechanism is not identical to caffeine. Like caffeine, theacrine antagonizes adenosine A1 and A2A receptors (the primary driver of wakefulness and reduced perception of effort), but rodent models (Feduccia 2012) additionally show dose-dependent increases in nucleus accumbens dopamine and locomotor activation that are blocked by both adenosine and dopamine-D1 antagonists — suggesting a dual adenosinergic-dopaminergic mechanism that caffeine does not fully replicate. This may explain the \"motivation\" quality users report and the absence of downregulation: chronic adenosine blockade alone should produce tolerance, but the concurrent dopaminergic signal appears to counterbalance receptor adaptation over an 8-week horizon. Human clinical data are limited but consistent. A double-blind crossover in habitual caffeine users (Ziegenfuss 2017) showed 300 mg theacrine improved reaction-time Bond-Lader alertness scores without the jitter-axis elevation that 150 mg caffeine produced in the same subjects. A separate 8-week safety and efficacy trial in 60 adults (Kuhman 2015) reported significant improvements in self-rated energy, focus, and concentration versus placebo at 200 and 300 mg/day with no adverse clinical findings. Community-tier evidence (r/Nootropics, forum writeups spanning 2015-2024) tends to converge on 100-200 mg as a mild-stim daily baseline, 250-300 mg for pre-workout or high-focus sessions, and 150 mg + 100 mg caffeine as a common synergy stack. Most users who transition from pure caffeine report similar energy with substantially less afternoon \"crash\" and easier sleep onset if taken before 2 PM. Practical considerations: theacrine is sold as a food-supplement ingredient in the US, EU, Australia, and most of Asia. It is NOT a controlled substance, not a prescription drug, and has no abuse liability signal in animal models. Quality matters — the vast majority of peer-reviewed human data used TeaCrine, a standardized ≥98% pure ingredient; some generic \"theacrine\" bulk powder has been found to be underdosed or contaminated with caffeine (independent COA testing, 2019-2021). Look for products that explicitly cite the TeaCrine trademark and provide a certificate of analysis. Theacrine is often stacked with L-theanine (100-200 mg) for an anxiolytic counterweight, with alpha-GPC (300 mg) for cholinergic contrast, and with dynamine (methylliberine, a faster-acting but shorter-duration analog) for a biphasic energy curve. It is not recommended for pregnancy, breastfeeding, uncontrolled hypertension, or anyone on MAOIs. The safety window at studied doses is wide, but the long-term profile beyond 8 weeks remains formally uncharacterized — community experience over 2-3 years of daily use suggests it holds up, but this is self-report data.",
        "activeIngredient": "Theacrine",
        "administrationRoute": "Oral",
        "mechanismOfAction": "Theacrine's primary pharmacodynamic signature is dual adenosine A1/A2A receptor antagonism, the same mechanism caffeine exploits to reduce perceived fatigue and suppress sleep drive. The 9-methyl and 2,6,8-trione modifications to the xanthine core shift its receptor affinity profile: rodent binding studies (Feduccia 2012) show theacrine binds A1 and A2A with lower affinity than caffeine on a per-molecule basis but produces comparable behavioral activation, suggesting differences in receptor kinetics or downstream coupling. The second mechanism — and the one that most clearly distinguishes theacrine from caffeine — is dopaminergic. In rodent microdialysis experiments, acute theacrine (24-48 mg/kg) increased nucleus accumbens dopamine and locomotor activity. This locomotor response was blocked by the dopamine-D1 antagonist SCH 23390 AND by the adenosine-receptor antagonist DPCPX, indicating the behavioral output requires BOTH adenosine blockade and D1 activation. Caffeine's locomotor effect is blocked only by adenosine antagonism. This divergence plausibly underlies theacrine's subjective \"motivation\" quality and may contribute to the absence of tolerance — because the dopaminergic signal maintains net stimulation even if adenosine-receptor sensitivity adapts. A third, lower-confidence mechanism involves mild adenosine triphosphate (ATP) conservation via inhibition of hepatic and adipose tissue breakdown pathways — the evidence for this is cell-culture tier and has not been verified in human tissue. Theacrine does NOT appreciably inhibit phosphodiesterase at physiological doses (unlike caffeine at high doses), does NOT block the GABA-A receptor, and does NOT significantly modulate serotonin or noradrenaline in available models. Pharmacokinetically, theacrine is orally bioavailable, peaks in plasma at ~60-90 minutes, and has a half-life of 16-20 hours in humans (He 2017) — substantially longer than caffeine's 5-hour half-life. Co-ingestion with caffeine increases theacrine AUC by roughly 100% (likely via shared CYP1A2 metabolism, with caffeine acting as a competitive substrate), while caffeine's own pharmacokinetics remain largely unchanged. This explains the widely-reported synergy of low-dose caffeine + theacrine stacks: caffeine sharpens the onset and extends theacrine's effective exposure without substantially increasing caffeine-specific side effects. Theacrine is metabolized primarily through hepatic demethylation, eventually converging on uric-acid-like terminal products. CYP1A2 is implicated but not exclusive; slow CYP1A2 metabolizers may experience extended duration and should adjust dosing accordingly.",
        "legalStatus": "Not approved for human use — research chemical",
        "warning": "For research purposes only. Not for human consumption."
      }
    },
    {
      "@context": "https://schema.org",
      "@type": "FAQPage",
      "mainEntity": [
        {
          "@type": "Question",
          "name": "How is theacrine different from caffeine?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Theacrine shares caffeine's adenosine A1/A2A antagonism but adds dopaminergic activation (Feduccia 2012, PMID 22771692) and has a 16-20 hour half-life versus caffeine's 5 hours. The practical differences: slower onset (60-90 minutes vs 20-40), less jitter and peripheral stimulation, no measurable tolerance at 8 weeks of daily use (Taylor 2016, PMID 27335344), and no withdrawal on cessation. Many users describe the subjective quality as 'motivation' or 'smooth energy' rather than caffeine's 'alertness.'"
          }
        },
        {
          "@type": "Question",
          "name": "Does theacrine really not build tolerance?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "The 8-week clinical data (Taylor 2016) show no measurable tolerance at 200-300 mg/day — no waning subjective effect, no cardiovascular adaptation, no need for dose escalation. Rodent locomotor data (Feduccia 2012) show the same pattern over 7 days where caffeine produces clear tolerance. The mechanism probably involves the dopaminergic signal counterbalancing adenosine-receptor desensitization. Long-term (>8 week) data are limited, so 'no tolerance ever' overstates the evidence — but across the best-characterized window, the tolerance resistance is real."
          }
        },
        {
          "@type": "Question",
          "name": "What's the optimal dose?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "100-200 mg in the morning is the community-tier sweet spot for most users. The clinical trials used 200-300 mg. Above 300 mg, effects tend to flatten or invert for many users, suggesting dopaminergic receptor saturation. Start at 100 mg for 1-2 weeks, then titrate up only if needed. When stacking with caffeine, reduce the theacrine dose by ~25% because caffeine doubles theacrine AUC (He 2017, PMID 28356193)."
          }
        },
        {
          "@type": "Question",
          "name": "Can I take theacrine every day?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Yes, the 8-week daily dosing trial (Taylor 2016, PMID 27335344) found no tolerance, no adverse clinical findings, and no withdrawal. Most users take it daily without cycling. Some prefer 5 days on / 2 days off for subjective freshness or to preserve sleep on off-days, but there's no pharmacological reason the cycle is necessary."
          }
        },
        {
          "@type": "Question",
          "name": "Will it mess up my sleep?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Almost certainly, if you take it after ~2 PM. The 16-20 hour half-life means a 200 mg morning dose still has ~40% of peak plasma at 10 PM. Take theacrine before noon only, and skip on days when uncompromised sleep is critical. No post-dose sleep aid effectively offsets it — the pharmacokinetics simply don't allow a same-day rescue."
          }
        },
        {
          "@type": "Question",
          "name": "Does it work better with caffeine?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Often yes. Caffeine doubles theacrine plasma AUC (He 2017, PMID 28356193), adds fast-onset alertness, and the combination tested in Ziegenfuss 2017 (PMID 28280478) outperformed either monotherapy for composite attention. A common starter combination is 125 mg theacrine + 100 mg caffeine morning. Reduce your usual caffeine ~30% the first time you add theacrine to avoid cardiovascular overshoot."
          }
        },
        {
          "@type": "Question",
          "name": "Is TeaCrine different from generic theacrine?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "TeaCrine is a ≥98% pure branded ingredient (Compound Solutions) used in most published clinical trials. Generic bulk theacrine has shown variable purity in independent testing — some underdosed, some adulterated with caffeine. If the supplement bottle doesn't cite the TeaCrine trademark and provide a COA, quality is unreliable. The clinical efficacy data technically only cover TeaCrine, not generic material."
          }
        },
        {
          "@type": "Question",
          "name": "Is theacrine legal and safe?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Theacrine is legal as a dietary-supplement ingredient in the US, EU, Canada, Australia, and most of Asia. It's not a controlled substance, not a prescription drug, and has no abuse liability signal in rodent or human studies. Safety at 100-300 mg/day is supported by 8 weeks of clinical exposure with no adverse findings. It is not on the 2024 WADA prohibited list, though competitive athletes should verify with their specific governing body."
          }
        },
        {
          "@type": "Question",
          "name": "Who should avoid it?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Anyone pregnant or breastfeeding, under 18, with uncontrolled hypertension, arrhythmia, or on MAOIs. Relative cautions include treated hypertension, anxiety disorders (dopaminergic activation can be anxiogenic), bipolar disorder, active gout, and concurrent use of strong CYP1A2 inhibitors like fluvoxamine or ciprofloxacin. If you're on any daily medication, check with your prescriber before starting."
          }
        },
        {
          "@type": "Question",
          "name": "What does theacrine stack well with?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "The most evidence-backed pairing is caffeine (see above). L-theanine (100-200 mg) is the most common anxiolytic counterweight. Alpha-GPC (300 mg) adds cholinergic depth for cognitive sessions. Dynamine (100 mg, methylliberine) creates a biphasic energy curve. Rhodiola rosea layers an adaptogen on top. Avoid stacking with other stimulants (DMHA, DMAA, yohimbine) — the sympathomimetic load compounds without additive benefit."
          }
        }
      ]
    },
    {
      "@context": "https://schema.org",
      "@type": "Organization",
      "@id": "https://www.bodyhackguide.co#organization",
      "name": "BodyHackGuide",
      "alternateName": "BHG",
      "url": "https://www.bodyhackguide.co",
      "logo": {
        "@type": "ImageObject",
        "url": "https://www.bodyhackguide.co/logo.png",
        "width": 512,
        "height": 512
      },
      "description": "Evidence-based research reference for peptides and nootropics. 124+ compound profiles, interactive dosing calculators, real-time vendor pricing, and trust-scored vendor reviews scored on a public, reproducible methodology applied to every vendor. BodyHackGuide and BHG Labs share common ownership, and we earn a commission on purchases through our links.",
      "foundingDate": "2024",
      "founder": {
        "@id": "https://www.bodyhackguide.co/about#person"
      },
      "sameAs": [
        "https://x.com/bodyhackguide",
        "https://reddit.com/r/BodyHackGuide",
        "https://reddit.com/r/BrainHackGuide",
        "https://reddit.com/r/Biohackingher",
        "https://discord.gg/Mhq5UdRYBA"
      ],
      "knowsAbout": [
        "Peptide research",
        "Nootropic research",
        "Biohacking",
        "Compound dosing",
        "Vendor transparency"
      ],
      "publishingPrinciples": "https://www.bodyhackguide.co/editorial-standards",
      "ethicsPolicy": "https://www.bodyhackguide.co/editorial-standards",
      "diversityPolicy": "https://www.bodyhackguide.co/editorial-standards"
    }
  ]
---

[Skip to content](#main-content)

## Research Use Only

This site is an **educational resource** for research compounds. We do **not endorse** human consumption of any compound. BodyHackGuide and **BHG Labs share common ownership**; we rank every vendor on the same public methodology, and we earn a commission on purchases through our links. By entering, you confirm you are **21 years of age or older** and agree to our [Terms](/terms) & [Privacy Policy](/privacy).

I'm 21+ — Enter SiteLeave site

  

[![BodyHackGuide](/assets/bodyhackguide-logo-DOzZNUyh.webp)BodyHackGuide ](/)

[Compare](/compare)[Wiki](/wiki)[Vendors](/vendors)[Deals](/deals)[Stacks](/stack-builder)[Nootropics](/nootropics)[Tools](/tools)

Learn

Community

Search ⌘K

[Sign In](/auth?returnTo=%2Fcompound%2Ftheacrine)

100K+ researchers trust BodyHackGuide — Join [r/BodyHackGuide](https://reddit.com/r/bodyhackguide) 

1.  [Home](/)
2.  [Compounds](/compare)
3.  Theacrine 

[Where to buy Theacrine](/buy/theacrine) [Theacrine coupon codes](/coupons/theacrine) [Theacrine protocol](/protocol/theacrine) [Alternatives to Theacrine](/alternatives-to/theacrine) [Theacrine side effects](/side-effects/theacrine)

1.  [Home](/)

3.  [Compounds](/compare)

5.  Theacrine 

# Theacrine

Nootropics Dietary Supplement (Food Ingredient) 

Download  PDF

Also known as: 1,3,7,9-tetramethyluric acid, TeaCrine, 1,3,7,9-tetramethyl-purine-2,6,8-trione 

Theacrine (1,3,7,9-tetramethyluric acid) is a purine alkaloid structurally related to caffeine, found naturally in Camellia assamica var. kucha — a tea cultivar grown in southern China and northern Vietnam — and in smaller amounts in Cupuaçu (Theobroma grandiflorum) seeds.

Half-Life:  16-20 hours (plasma); Tmax 60-90 minutes Route:  Oral MW:  224.22 g/mol [80 PubMed Studies](https://pubmed.ncbi.nlm.nih.gov/?term=theacrine%20OR%20%221%2C3%2C7%2C9-tetramethyluric%20acid%22%20OR%20TeaCrine%20cognition%20energy%20tolerance)

Last reviewed: May 4, 2026 

[

80

PubMed Studies



](https://pubmed.ncbi.nlm.nih.gov/?term=theacrine%20OR%20%221%2C3%2C7%2C9-tetramethyluric%20acid%22%20OR%20TeaCrine%20cognition%20energy%20tolerance)[

Nootropics

Category



](/wiki#cat-nootropics)

Dietary Supplement (Food Ingredient)

Research Stage

OverviewChemical InfoDosing & ProtocolsInteractionsResearchCompare PricesRelated

## Overview

### At A Glance

Mechanism 

Theacrine's primary pharmacodynamic signature is dual adenosine A1/A2A receptor antagonism, the same mechanism caffeine exploits to reduce perceived fatigue and suppress sleep drive. The 9-methyl and 2,6,8-trione modifications to the xanthine core shift its receptor affinity prof… 

Half-Life 

16-20 hours (plasma); Tmax 60-90 minutes

Routes 

Oral 

### Overview

Theacrine (1,3,7,9-tetramethyluric acid) is a purine alkaloid structurally related to caffeine, found naturally in Camellia assamica var. kucha — a tea cultivar grown in southern China and northern Vietnam — and in smaller amounts in Cupuaçu (Theobroma grandiflorum) seeds. It shares caffeine's xanthine backbone but carries an extra methyl group at the 9-position and a 2,6,8-trione oxidation pattern, giving it pharmacology that overlaps caffeine's adenosine-receptor antagonism while diverging in dopaminergic tone and tolerance development. The most widely studied form in human trials is the patented ingredient TeaCrine, a ≥98% pure synthetic equivalent used in most commercial nootropic and pre-workout formulas. The practical appeal of theacrine in community use rests on three observations: first, healthy adults taking 200-300 mg daily report stimulation subjectively comparable to 150-200 mg caffeine — but with less jitter, less heart-rate elevation, and a slower onset (~60-90 minutes) that many users describe as "smoother" than caffeine's 20-40 minute peak. Second, an 8-week daily-dosing study (Taylor 2016) found no meaningful development of tolerance at 200-300 mg/day, no withdrawal signs on cessation, and no shifts in resting heart rate, blood pressure, liver enzymes, or complete blood count — a tolerance profile that genuinely differs from caffeine, where habitual use produces documented receptor upregulation and dependence within 1-2 weeks. Third, co-administration with caffeine produces synergy: pharmacokinetic data (He 2017) show caffeine roughly doubles theacrine plasma exposure (AUC), likely by slowing hepatic clearance, so 125 mg theacrine + 150 mg caffeine often outperforms either compound alone for perceived focus and endurance. Mechanism is not identical to caffeine. Like caffeine, theacrine antagonizes adenosine A1 and A2A receptors (the primary driver of wakefulness and reduced perception of effort), but rodent models (Feduccia 2012) additionally show dose-dependent increases in nucleus accumbens dopamine and locomotor activation that are blocked by both adenosine and dopamine-D1 antagonists — suggesting a dual adenosinergic-dopaminergic mechanism that caffeine does not fully replicate. This may explain the "motivation" quality users report and the absence of downregulation: chronic adenosine blockade alone should produce tolerance, but the concurrent dopaminergic signal appears to counterbalance receptor adaptation over an 8-week horizon. Human clinical data are limited but consistent. A double-blind crossover in habitual caffeine users (Ziegenfuss 2017) showed 300 mg theacrine improved reaction-time Bond-Lader alertness scores without the jitter-axis elevation that 150 mg caffeine produced in the same subjects. A separate 8-week safety and efficacy trial in 60 adults (Kuhman 2015) reported significant improvements in self-rated energy, focus, and concentration versus placebo at 200 and 300 mg/day with no adverse clinical findings. Community-tier evidence (r/Nootropics, forum writeups spanning 2015-2024) tends to converge on 100-200 mg as a mild-stim daily baseline, 250-300 mg for pre-workout or high-focus sessions, and 150 mg + 100 mg caffeine as a common synergy stack. Most users who transition from pure caffeine report similar energy with substantially less afternoon "crash" and easier sleep onset if taken before 2 PM. Practical considerations: theacrine is sold as a food-supplement ingredient in the US, EU, Australia, and most of Asia. It is NOT a controlled substance, not a prescription drug, and has no abuse liability signal in animal models. Quality matters — the vast majority of peer-reviewed human data used TeaCrine, a standardized ≥98% pure ingredient; some generic "theacrine" bulk powder has been found to be underdosed or contaminated with caffeine (independent COA testing, 2019-2021). Look for products that explicitly cite the TeaCrine trademark and provide a certificate of analysis. Theacrine is often stacked with L-theanine (100-200 mg) for an anxiolytic counterweight, with alpha-GPC (300 mg) for cholinergic contrast, and with dynamine (methylliberine, a faster-acting but shorter-duration analog) for a biphasic energy curve. It is not recommended for pregnancy, breastfeeding, uncontrolled hypertension, or anyone on MAOIs. The safety window at studied doses is wide, but the long-term profile beyond 8 weeks remains formally uncharacterized — community experience over 2-3 years of daily use suggests it holds up, but this is self-report data.

## Chemical Information

IUPAC Name

Not yet available 

CAS Number

Not yet available 

Molecular Formula

Not yet available 

Molecular Mass

224.22 g/mol

## Dosing & Protocols

### Unlock Dosing Protocols

Free account gets you:

-   View beginner, intermediate & advanced protocols 
-   See weight-based dosing calculations 
-   Access cycle length & frequency data 

[Create free account](/auth)[Sign in](/auth)

2,800+ researchers already in

## Research

### Unlock Research Data

Free account gets you:

-   Browse PubMed study summaries 
-   See clinical trial phases & results 
-   Access mechanism of action details 

[Create free account](/auth)[Sign in](/auth)

2,800+ researchers already in

## Interactions

### Contraindications

Absolute contraindications: known theacrine or xanthine hypersensitivity; uncontrolled hypertension (systolic >160 or diastolic >100 mmHg); ventricular arrhythmia or symptomatic atrial fibrillation; MAOI therapy (phenelzine, tranylcypromine, selegiline at psychiatric doses); pregnancy; breastfeeding; age under 18.

Relative contraindications requiring clinician review: treated hypertension on beta-blockers, ACE inhibitors, or calcium-channel blockers; history of panic disorder or generalized anxiety disorder (dopaminergic activation can be anxiogenic in vulnerable individuals); bipolar disorder on stimulant-sensitive regimens; chronic kidney disease (eGFR <60) due to altered xanthine clearance; active gout or frequent hyperuricemia; concurrent use of high-dose caffeine (>400 mg/day) without first reducing caffeine intake; fluvoxamine, ciprofloxacin, or other strong CYP1A2 inhibitors.

Drug interactions documented or theoretical: MAOIs (theoretical dopaminergic crisis — avoid); oral contraceptives containing ethinyl estradiol (slow CYP1A2, may extend theacrine exposure — monitor); high-dose caffeine (additive sympathomimetic — dose-reduce both); stimulant ADHD medications (amphetamine, methylphenidate) — the dopaminergic overlap is theoretical but concerning enough to warrant prescriber awareness.

Pre-surgical: discontinue theacrine at least 48 hours before elective surgery due to the long half-life and theoretical cardiovascular sensitization under anesthesia.

Exercise/competitive athletics: theacrine is NOT on the 2024 WADA prohibited list. It is permitted in most sport-governing bodies including NCAA, IOC, and UCI. Competitive athletes should verify with their specific governing body before use.

Research Disclaimer

This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.

[Sign in for alerts ](/auth)

No listings found for Theacrine.

Get Theacrine Price Drop Alerts

Set a target price and we'll notify you when any vendor drops below it.

[Sign in to set alerts](/auth)

### Sign in to leave a review

Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with Theacrine.

[Sign in](/auth)

Current low

$39.99

as of Apr 7, 2026

7-day low

—

no 7d data yet

30-day low

—

no 30d data yet

30-day change

— 

baseline building

Tracking since Apr 7, 2026 · 4 data points

### Related Compounds

[View All](/wiki)

[

### 9-Me-BC (9-Methyl-β-carboline)

Nootropics Preclinical 

9-Methyl--carboline (9-Me-BC) is a synthetic -carboline alkaloid that has drawn nootropic-community interest for a preclinical property that is genuinely unusual among -carbolines: in rodent and cell-culture studies it appears to stimulate the dopaminergic phenotype - raising tyrosine hydroxylase, the number of differentiated dopamine neurons and dopamine content - while also showing neuroprotective, neurorestorative and anti-inflammatory effects, plus in-vitro MAO-A/MAO-B inhibition \[PMID:17913302, PMID:20374418, PMID:32285253\].

t½ Not characterized in humans (no pharmacokinetic data).  Community/anecdotal only: ~5-25 mg per day, oral. No validated or approved human dose exists. 

6 studies View Profile 

](/compound/9-mbc)[

### Bromantane

Nootropics Russia Approved 

Bromantane is an atypical psychostimulant and anxiolytic developed in the 1980s at the Zakusov Institute of Pharmacology of the Russian Academy of Medical Sciences, originally created as an adaptogen for Soviet military and elite athletic use and later approved in Russia for the treatment of neurasthenic and asthenic disorders under the trade name Ladasten.

34 studies View Profile 

](/compound/bromantane)[

### Dihexa

Nootropics Preclinical 

Dihexa is a synthetic peptide analogue of the angiotensin IV metabolite LVV-hemorphin-7, developed at Washington State University.

t½ Not characterized in humans. Dihexa was engineered for metabolic stability (resistant to plasma and enzymatic degradation) and blood-brain-barrier penetration; in preclinical work its central procognitive effects appear to outlast its plasma presence.  5 to 40 mg oral per day (anecdotal range; no established human dose) 

1 studies View Profile 

](/compound/dihexa)[

### Kavain

Nootropics Preclinical for isolated kavain (in-vitro and animal mechanistic data). Human randomized controlled trials exist for the parent standardized kava extract, of which kavain is the principal kavalactone; the single molecule itself has not been trialed alone. 

Kavain (kawain) is the principal kavalactone in kava (Piper methysticum) and the main compound behind kava's calming, anxiolytic effect.

t½ Not firmly established for isolated kavain in humans. Kavalactones are lipophilic and rapidly absorbed, with subjective effects generally lasting a few hours. Limited pharmacokinetic data preclude a precise elimination half-life.  50000-250000 

Preclinical View Profile 

](/compound/kavain)[

### KW-6356

Nootropics Phase 2b (program discontinued) 

KW-6356 is a selective adenosine A2A receptor antagonist/inverse agonist developed by Kyowa Kirin and studied for Parkinson's disease, both as monotherapy and as an add-on to levodopa.

Preclinical View Profile 

](/compound/kw-6356)[

### L-Theanine

Nootropics FDA Approved 

L-Theanine is a non-proteinogenic amino acid found almost exclusively in tea (Camellia sinensis) and a handful of edible mushrooms, and it has become the single most widely-used calm-focus nootropic in the modern supplement market — both on its own at 100-400mg doses and, even more prominently, as the classic 1:1 or 2:1 pair with caffeine that defines the "calm-focus" experiential signature of green tea and of virtually every serious nootropic stack.

t½ 1-3 hours (plasma); central CNS effect 3-5 hours 

1226 studies View Profile 

](/compound/l-theanine)

### Side-by-Side Comparisons

[All Comparisons](/compare)

[Theacrine vs Caffeine](/compare/theacrine-vs-caffeine "Theacrine vs Caffeine")

[

View Full Dosage Guide →

Protocols, calculator & safety for Theacrine



](/guides/dosage/theacrine)

### Related Articles

[All Posts](/blog)

[

#### Ion Peptide Review 2026: BPC-157, GLP-1s, Buccal Strips & Bioregulators

A complete look at Ion Peptide (ionpeptide.com) — 92 products spanning research peptides, GLP-1 agonists, NAD+/B12/glutathione buccal strips, copper peptide topicals, Khavinson bioregulators, and PDRN. We cover pricing, testing, shipping, unique offerings, and how they compare to other vendors on BodyHackGuide.

4/21/2026 ](/blog/ion-peptide-review-2026)[

#### We Compared 8 Focus Nootropics for 90 Days — Here's What Actually Works

We tested 8 popular focus nootropics over 90 days using objective metrics — reaction time, deep work hours, and daily focus ratings. Here are the honest results, including costs and side effects.

4/3/2026 ](/blog/best-focus-nootropics-90-day-comparison)[

#### Nootropic Pouches: Everything You Need to Know

Sublingual nootropic pouches are changing how we take cognitive enhancers. This guide covers the science of buccal absorption, compares available products, and breaks down ingredients in the leading formulations.

4/1/2026 ](/blog/nootropic-pouches-guide)

### Research Score

23 

80 PubMed studies

### Quality Indicators

Data Completeness

63% 

Description 

Mechanism of Action 

Chemical Data 

Dosing Protocols 

Safety Profile 

PubMed Studies 

Interactions 

Vendor Listings 

Research Credibility

80 PubMed studies 

Well-researched compound

### Quick Facts

Half-Life

16-20 hours (plasma); Tmax 60-90 minutes

Molecular Weight

224.22 g/mol

Administration

Oral

Trial Phase

Dietary Supplement (Food Ingredient)

[Full Dosage Guide](/guides/dosage/theacrine)[Calculate Your Dose](/tools/reconstitution)

Research Disclaimer

This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.

## Frequently Asked Questions

How is theacrine different from caffeine?

Theacrine shares caffeine's adenosine A1/A2A antagonism but adds dopaminergic activation (Feduccia 2012, PMID 22771692) and has a 16-20 hour half-life versus caffeine's 5 hours. The practical differences: slower onset (60-90 minutes vs 20-40), less jitter and peripheral stimulation, no measurable tolerance at 8 weeks of daily use (Taylor 2016, PMID 27335344), and no withdrawal on cessation. Many users describe the subjective quality as 'motivation' or 'smooth energy' rather than caffeine's 'alertness.'

Does theacrine really not build tolerance?

The 8-week clinical data (Taylor 2016) show no measurable tolerance at 200-300 mg/day — no waning subjective effect, no cardiovascular adaptation, no need for dose escalation. Rodent locomotor data (Feduccia 2012) show the same pattern over 7 days where caffeine produces clear tolerance. The mechanism probably involves the dopaminergic signal counterbalancing adenosine-receptor desensitization. Long-term (>8 week) data are limited, so 'no tolerance ever' overstates the evidence — but across the best-characterized window, the tolerance resistance is real.

What's the optimal dose?

100-200 mg in the morning is the community-tier sweet spot for most users. The clinical trials used 200-300 mg. Above 300 mg, effects tend to flatten or invert for many users, suggesting dopaminergic receptor saturation. Start at 100 mg for 1-2 weeks, then titrate up only if needed. When stacking with caffeine, reduce the theacrine dose by ~25% because caffeine doubles theacrine AUC (He 2017, PMID 28356193).

Can I take theacrine every day?

Yes, the 8-week daily dosing trial (Taylor 2016, PMID 27335344) found no tolerance, no adverse clinical findings, and no withdrawal. Most users take it daily without cycling. Some prefer 5 days on / 2 days off for subjective freshness or to preserve sleep on off-days, but there's no pharmacological reason the cycle is necessary.

Will it mess up my sleep?

Almost certainly, if you take it after ~2 PM. The 16-20 hour half-life means a 200 mg morning dose still has ~40% of peak plasma at 10 PM. Take theacrine before noon only, and skip on days when uncompromised sleep is critical. No post-dose sleep aid effectively offsets it — the pharmacokinetics simply don't allow a same-day rescue.

Does it work better with caffeine?

Often yes. Caffeine doubles theacrine plasma AUC (He 2017, PMID 28356193), adds fast-onset alertness, and the combination tested in Ziegenfuss 2017 (PMID 28280478) outperformed either monotherapy for composite attention. A common starter combination is 125 mg theacrine + 100 mg caffeine morning. Reduce your usual caffeine ~30% the first time you add theacrine to avoid cardiovascular overshoot.

Is TeaCrine different from generic theacrine?

TeaCrine is a ≥98% pure branded ingredient (Compound Solutions) used in most published clinical trials. Generic bulk theacrine has shown variable purity in independent testing — some underdosed, some adulterated with caffeine. If the supplement bottle doesn't cite the TeaCrine trademark and provide a COA, quality is unreliable. The clinical efficacy data technically only cover TeaCrine, not generic material.

Is theacrine legal and safe?

Theacrine is legal as a dietary-supplement ingredient in the US, EU, Canada, Australia, and most of Asia. It's not a controlled substance, not a prescription drug, and has no abuse liability signal in rodent or human studies. Safety at 100-300 mg/day is supported by 8 weeks of clinical exposure with no adverse findings. It is not on the 2024 WADA prohibited list, though competitive athletes should verify with their specific governing body.

Who should avoid it?

Anyone pregnant or breastfeeding, under 18, with uncontrolled hypertension, arrhythmia, or on MAOIs. Relative cautions include treated hypertension, anxiety disorders (dopaminergic activation can be anxiogenic), bipolar disorder, active gout, and concurrent use of strong CYP1A2 inhibitors like fluvoxamine or ciprofloxacin. If you're on any daily medication, check with your prescriber before starting.

What does theacrine stack well with?

The most evidence-backed pairing is caffeine (see above). L-theanine (100-200 mg) is the most common anxiolytic counterweight. Alpha-GPC (300 mg) adds cholinergic depth for cognitive sessions. Dynamine (100 mg, methylliberine) creates a biphasic energy curve. Rhodiola rosea layers an adaptogen on top. Avoid stacking with other stimulants (DMHA, DMAA, yohimbine) — the sympathomimetic load compounds without additive benefit.

## Research Tools

[

### Peptide Calculator

Reconstitution & syringe units



](/tools/reconstitution)[

### Reconstitution Guide

How to mix, step by step



](/guides/how-to-reconstitute-peptides)[

### Nasal Spray Calc

mL per actuation



](/tools/intranasal)[

### Half-Life Visualizer

Decay curves



](/tools/halflife)

## Related Compounds

[View All](/wiki)

[

### 9-Me-BC (9-Methyl-β-carboline)

Nootropics Preclinical 

9-Methyl--carboline (9-Me-BC) is a synthetic -carboline alkaloid that has drawn nootropic-community interest for a preclinical property that is genuinely unusual among -carbolines: in rodent and cell-culture studies it appears to stimulate the dopaminergic phenotype - raising tyrosine hydroxylase, the number of differentiated dopamine neurons and dopamine content - while also showing neuroprotective, neurorestorative and anti-inflammatory effects, plus in-vitro MAO-A/MAO-B inhibition \[PMID:17913302, PMID:20374418, PMID:32285253\].

t½ Not characterized in humans (no pharmacokinetic data).  Community/anecdotal only: ~5-25 mg per day, oral. No validated or approved human dose exists. 

6 studies View Profile 

](/compound/9-mbc)[

### Bromantane

Nootropics Russia Approved 

Bromantane is an atypical psychostimulant and anxiolytic developed in the 1980s at the Zakusov Institute of Pharmacology of the Russian Academy of Medical Sciences, originally created as an adaptogen for Soviet military and elite athletic use and later approved in Russia for the treatment of neurasthenic and asthenic disorders under the trade name Ladasten.

34 studies View Profile 

](/compound/bromantane)[

### Dihexa

Nootropics Preclinical 

Dihexa is a synthetic peptide analogue of the angiotensin IV metabolite LVV-hemorphin-7, developed at Washington State University.

t½ Not characterized in humans. Dihexa was engineered for metabolic stability (resistant to plasma and enzymatic degradation) and blood-brain-barrier penetration; in preclinical work its central procognitive effects appear to outlast its plasma presence.  5 to 40 mg oral per day (anecdotal range; no established human dose) 

1 studies View Profile 

](/compound/dihexa)[

### Kavain

Nootropics Preclinical for isolated kavain (in-vitro and animal mechanistic data). Human randomized controlled trials exist for the parent standardized kava extract, of which kavain is the principal kavalactone; the single molecule itself has not been trialed alone. 

Kavain (kawain) is the principal kavalactone in kava (Piper methysticum) and the main compound behind kava's calming, anxiolytic effect.

t½ Not firmly established for isolated kavain in humans. Kavalactones are lipophilic and rapidly absorbed, with subjective effects generally lasting a few hours. Limited pharmacokinetic data preclude a precise elimination half-life.  50000-250000 

Preclinical View Profile 

](/compound/kavain)[

### KW-6356

Nootropics Phase 2b (program discontinued) 

KW-6356 is a selective adenosine A2A receptor antagonist/inverse agonist developed by Kyowa Kirin and studied for Parkinson's disease, both as monotherapy and as an add-on to levodopa.

Preclinical View Profile 

](/compound/kw-6356)[

### L-Theanine

Nootropics FDA Approved 

L-Theanine is a non-proteinogenic amino acid found almost exclusively in tea (Camellia sinensis) and a handful of edible mushrooms, and it has become the single most widely-used calm-focus nootropic in the modern supplement market — both on its own at 100-400mg doses and, even more prominently, as the classic 1:1 or 2:1 pair with caffeine that defines the "calm-focus" experiential signature of green tea and of virtually every serious nootropic stack.

t½ 1-3 hours (plasma); central CNS effect 3-5 hours 

1226 studies View Profile 

](/compound/l-theanine)

## Side-by-Side Comparisons

[All Comparisons](/compare)

Compare Theacrine head-to-head: mechanism, half-life, dosing, safety, and live pricing.

[Theacrine vs Caffeine](/compare/theacrine-vs-caffeine "Theacrine vs Caffeine")

Free 2026 Peptide Cheat Sheet — 50 pages, PDF

Reconstitution math, concentration charts, half-lives, and vendor trust tiers. The reference we wish we had on day one.

[Download Free](/guides/peptide-cheat-sheet-download?utm_source=compound-theacrine)

### Need bloodwork before starting?

Full hormone + metabolic panels from Anabolic Insights. Code CHONCH  for first-order discount.

[Order Bloodwork](https://anabolicinsights.ai/?ref=nwm2zjb)

![BodyHackGuide](/assets/bodyhackguide-logo-DOzZNUyh.webp)

### BodyHackGuide

Your biohacking research hub — compound pricing, brain health protocols, dosing tools, and vendor reviews.

[support@bodyhackguide.co](mailto:support@bodyhackguide.co)

[](https://discord.gg/Mhq5UdRYBA)[](https://reddit.com/r/BodyHackGuide)[](https://x.com/bodyhackguide)

Explore

#### Explore

-   [Compare prices](/compare)
-   [Research suppliers](/vendors)
-   [Deals](/deals)
-   [Coupons](/coupons)
-   [Nootropics](/nootropics)
-   [Brain health](/brain-health)
-   [Blog](/blog)
-   [Guides](/guides)

Tools

#### Tools

-   [Reconstitution](/tools/reconstitution)
-   [Dosage calculator](/tools/dosage)
-   [Half-life visualizer](/tools/halflife)
-   [COA lookup](/tools/coa)
-   [Cost calculator](/tools/cost-calculator)
-   [Stack builder](/stack-builder)
-   [All tools →](/tools)

Trust & vendors

#### Trust & vendors

-   [Vendor directory](/vendors)
-   [Trust scorecard](/vendors/scorecard)
-   [Get BHG verified](/vendors/get-vetted)
-   [Scoring methodology](/vendors/methodology)
-   [Peptide cheatsheet](/guides/peptide-cheat-sheet-download)

Company

#### Company

-   [About](/about)
-   [Affiliate disclosure](/affiliate-disclosure)
-   [Editorial standards](/editorial-standards)
-   [Creators](/creators)
-   [Coaches](/coaches)
-   [Privacy](/privacy)
-   [Terms](/terms)
-   [Full site directory →](/site-directory)

**Ownership & Affiliate Disclosure:** BodyHackGuide and BHG Labs share common ownership. We rank every vendor on the same public, reproducible [methodology](/vendors/methodology), and we earn a commission from purchases made through our links at no extra cost to you. Full details in our [affiliate disclosure](/affiliate-disclosure).

**Research Disclaimer:** All compounds listed are for laboratory and research purposes only. Not for human consumption. This site does not sell, distribute, or promote any products. Always consult a qualified healthcare professional and comply with local regulations.

© 2026 BodyHackGuide. All rights reserved. · [Terms](/terms) · [Privacy](/privacy)

hi 👋